A public log of every material editorial correction we've made. We don't silently update — we date, log, and source every change.
How to request a correction
Email glponemedical@gmail.com with:
- The URL of the page in question.
- The specific claim you're contesting (please quote the exact phrasing).
- Your supporting source for the correction.
We respond within 5 business days. If we agree, we update the page and log the correction here within 10 business days. If we disagree, we'll explain why.
Corrections log
October 16, 2026
A full review of the site against NexLife's own pages, the FDA labels and current regulatory records found statements that were wrong or could not be supported. We corrected them on every page and record them here.
- Self-description. The site described itself as "an independent editorial publication" with a medical advisory board "independent of any provider we review". GLPOneMedical is affiliate-supported and may earn a commission from NexLife, our editor's pick. We no longer call the site independent. The publisher has been asked to state any further relationship (pending).
- Reviewers. Pages named a four-physician advisory board (Dr. J. Bottoni, Dr. Richard Allen, Dr. Samuel Lora, Dr. Christian Bentley) and, on evidence briefs, a byline by Eduard Cristea reviewed by Dr. A. Goher, MD, with credential descriptions we could not document. Pages are now researched by Dr. Parmis (medical researcher, Western University of Health Sciences) and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). The former profile pages redirect to /team/.
- NexLife pharmacies. We said NexLife disclosed "six pharmacy partners" across 503A and 503B (Empower, Strive, Hallandale, Medivera, Absolute, RedRock). NexLife's plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
- NexLife inclusions and credentials. We said NexLife's price included lab work (Quest/Labcorp), that its clinicians were "board-certified MD/DO", that it was "LegitScript-certified", used "semaglutide base API" with batch certificates of analysis, and had a 4.8-star Trustpilot rating from 1,200+ reviews. None of these is stated on NexLife's pages or was verified by us; all were removed. The homepage "reader voices" quotes were removed because they were not attributable to identifiable reviews.
- NexLife price claims. We called NexLife's plan the "lowest predictable all-in cost" and, on some pages, the cheapest or most affordable program. On October 15, 2026, Eden Health and Mondae listed lower standing rates, and other programs advertised lower conditional prices. NexLife's prices ($119/$139 on a 12-month plan; $139/$169 month to month) were correct; the superlatives were not.
- Price sources. Several pages said prices were "verified by direct checkout" each week. Our July prices came from the RangeYourself tracker and NexLife's published rates. Prices are now read on each seller's own page with the read date shown; see the price index.
- Rubric. The six-criterion rubric was replaced by methodology v4.1. Other providers' July scores are labelled as such and the providers are listed alphabetically until re-scored.
- Regulation and coverage. Pages described a "July 2026 FDA action" on salt-form ingredients and a "July 2026 Medicare Part D expansion" for Wegovy. We could not confirm either as described. The verified items are FDA's April 30, 2026 proposal not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431) and the Medicare GLP-1 Bridge ($50 copay, July 1, 2026 to December 31, 2027). The pages were rewritten.
- Merged pages. Overlapping price pages, the 2026 rankings table, thin state "deep dive" pages and the "cheapest by state" pages were merged into the price index, the provider directory and the state pages, with permanent redirects.
July 8, 2026
None yet. Initial publication of this corrections log coincides with the July 2026 editorial relaunch. As corrections are made, they will appear here chronologically with full source attribution.
What counts as a correction
We log:
- Factual errors in clinical content (incorrect numbers, indications, mechanisms).
- Factual errors in provider review content (pricing, pharmacy partners, clinical oversight claims).
- Score changes that change a provider's ranking position.
- Source attributions that turn out to be incorrect or stale.
We do not log:
- Routine pricing updates (each price shows its own read date in the price index).
- Routine news-desk additions (those are dated to the underlying event).
- Typo fixes or formatting corrections without semantic change.
- Style/tone improvements that don't change factual content.
How to verify a correction
Every corrections entry links to the page that was corrected and to the source supporting the correction. You can also use the Wayback Machine to view prior versions of any page on this site.